上皮性卵巢癌相关肿瘤抗原的自身抗体。
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.
机构信息
Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology, Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84101, Israel.
出版信息
J Oncol. 2009;2009:581939. doi: 10.1155/2009/581939. Epub 2010 Jan 17.
Abstract
This review will focus on recent knowledge related to circulating autoantibodies (AAbs) to tumor-associated antigens (TAAs) in epithelial ovarian carcinoma. So far, the following TAAs have been identified to elicit circulating AAbs in epithelial ovarian carcinoma: p53, homeobox proteins (HOXA7, HOXB7), heat shock proteins (HSP-27, HSP-90), cathepsin D, cancer-testis antigens (NY-ESO-1/LAGE-1), MUC1, GIPC-1, IL-8, Ep-CAM, and S100A7. Since AAbs to TAAs have been identified in the circulation of patients with early-stage cancer, it has been speculated that the assessment of a panel of AAbs specific for epithelial ovarian carcinoma TAAs might hold great potential as a novel tool for early diagnosis of epithelial ovarian carcinoma.
摘要
这篇综述将重点介绍与上皮性卵巢癌相关的循环肿瘤相关抗原（TAAs）自身抗体（AAbs）的最新知识。迄今为止，已经确定以下 TAAs 在上皮性卵巢癌中引起循环 AAbs：p53、同源盒蛋白（HOXA7、HOXB7）、热休克蛋白（HSP-27、HSP-90）、组织蛋白酶 D、癌睾丸抗原（NY-ESO-1/LAGE-1）、MUC1、GIPC-1、IL-8、Ep-CAM 和 S100A7。由于已经在上皮性卵巢癌早期患者的循环中检测到针对 TAAs 的 AAbs，因此有人推测，评估一组针对上皮性卵巢癌 TAAs 的 AAbs 可能具有作为上皮性卵巢癌早期诊断的新型工具的巨大潜力。
相似文献
1
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.上皮性卵巢癌相关肿瘤抗原的自身抗体。
J Oncol. 2009;2009:581939. doi: 10.1155/2009/581939. Epub 2010 Jan 17.
2
Autoantibodies to tumor-associated antigens in breast carcinoma.乳腺癌相关肿瘤抗原的自身抗体。
J Oncol. 2010;2010:264926. doi: 10.1155/2010/264926. Epub 2010 Nov 21.
3
Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma.乳腺癌中针对肿瘤相关抗原定制面板的自身抗体。
J Oncol. 2011;2011:982425. doi: 10.1155/2011/982425. Epub 2011 Mar 3.
4
Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.系统评价：肿瘤相关抗原自身抗体与卵巢癌早期检测。
Gynecol Oncol. 2017 Nov;147(2):465-480. doi: 10.1016/j.ygyno.2017.07.138. Epub 2017 Aug 8.
5
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.NY-ESO-1和LAGE-1癌胚抗原是上皮性卵巢癌免疫治疗的潜在靶点。
Cancer Res. 2003 Sep 15;63(18):6076-83.
6
Autoantibodies against heat shock proteins as biomarkers for the diagnosis and prognosis of cancer.抗热休克蛋白自身抗体作为癌症诊断和预后的生物标志物。
Cancer Biomark. 2017;18(2):105-116. doi: 10.3233/CBM-160117.
7
NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.NY-ESO-1/LAGE-1与MAGE-A癌症/睾丸抗原的共表达：一项组织芯片研究
Int J Cancer. 2005 Jul 20;115(6):960-6. doi: 10.1002/ijc.20953.
8
Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.肿瘤相关自身抗体在肺癌早期诊断中的意义
Clin Respir J. 2018 Jun;12(6):2020-2028. doi: 10.1111/crj.12769. Epub 2018 Feb 15.
9
[Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma].[NY-ESO-1和LAGE-1癌胚抗原在肝细胞癌中的表达]
Zhonghua Bing Li Xue Za Zhi. 2005 Apr;34(4):202-5.
10
Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients.在印度乳腺癌患者中检测到针对TYMS和PDLIM1蛋白的自身抗体，作为循环特征。
Proteomics Clin Appl. 2016 May;10(5):564-73. doi: 10.1002/prca.201500138.
引用本文的文献
1
Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy.食管癌中癌-睾丸抗原的表达及其在免疫治疗中的进展。
J Cancer Res Clin Oncol. 2019 Feb;145(2):281-291. doi: 10.1007/s00432-019-02840-3. Epub 2019 Jan 17.
2
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.前列腺癌中针对致癌性ERG蛋白的自身抗体：在与C-MYC、AMACR和HERV-K Gag组成的检测组中用于诊断和预后的潜在用途。
Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126.
3
Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.血清抗p53致癌蛋白抗体免疫在卵巢癌中的预后作用：一项系统评价和荟萃分析
PLoS One. 2015 Oct 9;10(10):e0140351. doi: 10.1371/journal.pone.0140351. eCollection 2015.
4
Plasma immune analytes in patients with epithelial ovarian cancer.上皮性卵巢癌患者的血浆免疫分析物
Cytokine. 2015 May;73(1):108-13. doi: 10.1016/j.cyto.2015.01.035. Epub 2015 Mar 3.
5
Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma.挖掘人类自身抗体库：从一名胸腺瘤患者中分离出强效白细胞介素-17A中和单克隆抗体。
MAbs. 2014;6(6):1608-20. doi: 10.4161/mabs.36292.
6
Autoantibody signature for the serologic detection of ovarian cancer.用于卵巢癌血清学检测的自身抗体特征
J Proteome Res. 2015 Jan 2;14(1):578-86. doi: 10.1021/pr500908n. Epub 2014 Nov 17.
7
Serum autoantibody measurement for the detection of hepatocellular carcinoma.用于检测肝细胞癌的血清自身抗体检测
PLoS One. 2014 Aug 5;9(8):e103867. doi: 10.1371/journal.pone.0103867. eCollection 2014.
8
The immunomodulating roles of glycoproteins in epithelial ovarian cancer.糖蛋白在上皮性卵巢癌中的免疫调节作用。
Front Biosci (Elite Ed). 2012 Jan 1;4(2):631-50. doi: 10.2741/405.
9
Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.针对自身/肿瘤抗原的 T 细胞耐受：癌症患者和健康供体中针对 p53 的自发 CD4+ 而非 CD8+ T 细胞反应。
PLoS One. 2011;6(8):e23651. doi: 10.1371/journal.pone.0023651. Epub 2011 Aug 12.
10
Comparison of candidate serologic markers for type I and type II ovarian cancer.比较 I 型和 II 型卵巢癌候选血清标志物。
Gynecol Oncol. 2011 Sep;122(3):560-6. doi: 10.1016/j.ygyno.2011.05.039. Epub 2011 Jun 24.
本文引用的文献
1
Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.患者来源的肿瘤反应性抗体作为卵巢癌的诊断标志物。
Gynecol Oncol. 2009 Oct;115(1):112-120. doi: 10.1016/j.ygyno.2009.06.031. Epub 2009 Jul 31.
2
HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study.绝经前女性正常子宫内膜中的HOXA甲基化与卵巢癌的存在相关：一项原理验证研究。
Int J Cancer. 2009 Nov 1;125(9):2214-8. doi: 10.1002/ijc.24599.
3
p53 autoantibodies, cytokine levels and ovarian carcinogenesis.p53自身抗体、细胞因子水平与卵巢癌发生
Gynecol Oncol. 2009 Jul;114(1):12-7. doi: 10.1016/j.ygyno.2009.03.028. Epub 2009 Apr 26.
4
Ovarian cancer.卵巢癌
Annu Rev Pathol. 2009;4:287-313. doi: 10.1146/annurev.pathol.4.110807.092246.
5
Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary.靶向GIPC1的天然人类自身抗体可识别乳腺癌和卵巢癌中的差异表达。
BMC Cancer. 2008 Aug 24;8:247. doi: 10.1186/1471-2407-8-247.
6
Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.携带遗传性BRCA突变女性发生浆液性癌前病变（“p53特征”）的风险因素。
Gynecol Oncol. 2008 Nov;111(2):226-32. doi: 10.1016/j.ygyno.2008.07.018. Epub 2008 Aug 21.
7
Autoantibodies as potential biomarkers for breast cancer.自身抗体作为乳腺癌的潜在生物标志物。
Breast Cancer Res. 2008;10(3):R40. doi: 10.1186/bcr2091. Epub 2008 May 7.
8
Cathepsin D--many functions of one aspartic protease.组织蛋白酶D——一种天冬氨酸蛋白酶的多种功能
Crit Rev Oncol Hematol. 2008 Oct;68(1):12-28. doi: 10.1016/j.critrevonc.2008.02.008. Epub 2008 Apr 8.
9
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.卵巢癌的早期检测与治疗：基于一种新的致癌模型，从早期阶段向疾病最小体积的转变。
Am J Obstet Gynecol. 2008 Apr;198(4):351-6. doi: 10.1016/j.ajog.2008.01.005.
10
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.盆腔浆液性癌的候选前体（p53特征）及其在携带BRCA突变女性的卵巢和输卵管中的患病率。
Gynecol Oncol. 2008 May;109(2):168-73. doi: 10.1016/j.ygyno.2008.01.012. Epub 2008 Mar 14.
Zotero 插件